TY - JOUR
T1 - SOHO State of the Art Updates and Next Questions
T2 - BTK inhibitors combined with chemoimmunotherapy in CLL, the best of both worlds?
AU - Thompson, Philip A.
N1 - Publisher Copyright:
© 2021
PY - 2022/4
Y1 - 2022/4
N2 - Chemoimmunotherapy (CIT) remains a standard-of-care in many regions for first line (1L) therapy of CLL. In fit patients, fludarabine, cyclophosphamide, and rituximab (FCR) has the advantage of achieving undetectable measurable residual disease (MRD) with time-limited treatment and prolonged treatment-free remissions with a plateau on the PFS curve, but have several limitations, most notably the inferior PFS and survival outcomes for patients with unmutated IGHV compared to ibrutinib + rituximab seen in the E1912 study and a risk for long-term toxicities such as therapy-related myeloid neoplasms. Given the nonoverlapping toxicity profile with CIT and its efficacy in patients with high risk genomics, ibrutinib is a potentially useful agent to combine with CIT, with the aim of achieving deep and durable remissions, with time-limited treatment. Three recent phase 2 studies have combined ibrutinib with chemoimmunotherapy, utilizing different approaches in terms of patient selection, sequencing and duration of therapy and choice of monoclonal antibody. These studies all demonstrated favorable toxicity profiles and higher rates of undetectable MRD than with any other previously utilized 1L regimen. This review will focus on this novel treatment approach in CLL.
AB - Chemoimmunotherapy (CIT) remains a standard-of-care in many regions for first line (1L) therapy of CLL. In fit patients, fludarabine, cyclophosphamide, and rituximab (FCR) has the advantage of achieving undetectable measurable residual disease (MRD) with time-limited treatment and prolonged treatment-free remissions with a plateau on the PFS curve, but have several limitations, most notably the inferior PFS and survival outcomes for patients with unmutated IGHV compared to ibrutinib + rituximab seen in the E1912 study and a risk for long-term toxicities such as therapy-related myeloid neoplasms. Given the nonoverlapping toxicity profile with CIT and its efficacy in patients with high risk genomics, ibrutinib is a potentially useful agent to combine with CIT, with the aim of achieving deep and durable remissions, with time-limited treatment. Three recent phase 2 studies have combined ibrutinib with chemoimmunotherapy, utilizing different approaches in terms of patient selection, sequencing and duration of therapy and choice of monoclonal antibody. These studies all demonstrated favorable toxicity profiles and higher rates of undetectable MRD than with any other previously utilized 1L regimen. This review will focus on this novel treatment approach in CLL.
KW - Chemoimmunotherapy
KW - Combination
KW - Ibrutinib
KW - iFCG
KW - iFCR
UR - http://www.scopus.com/inward/record.url?scp=85119284794&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85119284794&partnerID=8YFLogxK
U2 - 10.1016/j.clml.2021.09.012
DO - 10.1016/j.clml.2021.09.012
M3 - Review article
C2 - 34774461
AN - SCOPUS:85119284794
SN - 2152-2650
VL - 22
SP - 205
EP - 209
JO - Clinical Lymphoma, Myeloma and Leukemia
JF - Clinical Lymphoma, Myeloma and Leukemia
IS - 4
ER -